KRAS and cancer: Moreover, the data sets we examined were derived by profiling cancers from patients who had not received medical treatment; hence the relationship of drugs or drug resistance to synthetic lethality has not been examined, and we would not have detected the recently reported amplification of wild type KRAS in a COAD with a mutant BRAF gene (Ahronian et al., 2015).